Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial

• Dennis L. Kelleher ,

  * E-mail: dennis.l.kelleher@gsk.com

  Affiliation Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Rashmi S. Mehta,

  Affiliation Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Bernadette M. Jean-Francois,

  Affiliation GlaxoSmithKline Australia Pty Ltd, Melbourne, Australia

  ⨯
• Andrew F. Preece,

  Affiliation Respiratory Medicines Development Center, GlaxoSmithKline, Stockley Park West, United Kingdom

  ⨯
• James Blowers,

  Affiliation Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• Glenn D. Crater,

  Affiliation GlaxoSmithKline, Mississauga, Canada

  ⨯
• Paul Thomas

  Affiliation Medicines Research Unit, GlaxoSmithKline, New South Wales, Australia

  ⨯